Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vibepolimab + Putilimab + Bevacizumab in Recurrent EGFR-positive Glioblastoma (Phase II, Single-arm)
ChiCTR2600125865Phase 2Not yet recruiting
- Sponsor
- Department of Neurosurgery, Tangdu Hospital
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vibepolimab, putilimab and bevacizumab in glioblastoma (GBM), sponsored by Department of Neurosurgery, Tangdu Hospital. Primary endpoint: Progression-Free Survival. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
vibepolimabputilimabbevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2600125865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125865.